AI tool for COVID-19 produces significant results

10th August 2020

EIT Health project to aid personalised treatment demonstrates 50% reduction in mortality

A recent study published in the journal Clinical Infectious Diseases has demonstrated that the use of an artificial intelligence tool developed by an EIT Health project led to a significant reduction in mortality rates amongst hospitalised COVID-19 patients, including elderly and at-risk populations.1

The tool is the outcome of a project named Digital Control Centre for COVID-19, and was initiated in April 2020 by EIT Health partners through EIT Health’s Rapid Response programme, which is supported by the EIT Crisis Response Initiative. As part of the EIT Crisis Response Initiative, this project directly contributes to the European Union’s response to the COVID-19 pandemic.

The tool has undergone development and validation, and has shown early success in the stratification and personalisation of treatment for patients with serious COVID-19, leading to improved treatment responses and, ultimately, a 50% reduction in mortality rates.

As of early August, there have been over 18 million cases of COVID-19 worldwide, and it has led to the death of over 689,000 people.2 The main cause of death for patients with COVID-19 is respiratory failure, however many patients experiencing respiratory symptoms can be effectively treated if adequate care is provided at the right time.3

In many countries, we are seeing deaths from COVID-19 fall as a result of the highly committed work of our healthcare professionals. Additionally, a greater understanding of the trajectory of the disease and its impact on humans, and the availability of better equipment and technology have armed us in the fight against the disease. Health innovation has been a crucial component of our growing strength of response to COVID-19, and has afforded us the opportunity to bring new solutions to improve our ability to overcome the impact of the disease. I am very proud of the early results demonstrated by our ‘Digital Control Centre for COVID-19’ project, which has been rapidly implemented and is already showing its potential to save lives. We look forward to further validation and will work to make it available for as many patients as possible across the globe,” said Jan-Philipp Beck, CEO of EIT Health.

The observational cohort study was conducted amongst 786 patients admitted to Hospital Clinic, Barcelona. Results also demonstrated that the tool was able to predict, with 90% accuracy, the trajectory of the disease in individual patients, to allow for timely and appropriate treatment. Use of the tool led improvements in patients’ condition at day five amongst 93.9% of patients treated with a personalised therapy approach.

How it works

The tool works by analysing the data of patients who are hospitalised with COVID-19 and are experiencing respiratory symptoms. The tool can define three distinct clinical pattern stratifications which reflect differing symptom complications – inflammation, co-infection and thrombosis. Early knowledge of these symptomatic patterns, each of which confers various clinical complications, leads to differing therapeutic approaches and subsequent personalised treatment decisions.

Researchers at Hospital Clinic Barcelona-IDIBAPS created the artificial intelligence solution capable of analysing, in real time, more than a trillion anonymised data points of COVID-19 patients, identifying clinical patterns and suggesting personalised treatments. The solution provides a real-time control centre for all COVID-19 patients admitted to hospital, under the supervision of an expert in infectious diseases.

“The artificial-intelligence system that we have built is capable of supporting clinicians in the early diagnosis of patients more prone to develop complications, and thus we have been able to provide timely and personalised treatments. This ‘Central Control System’ can be used for multiple applications beyond COVID-19 and represents a clear example of how AI can improve medicine and health outcomes,” said Carolina García-Vidal, Hospital Clínic de Barcelona.

The solution will now be validated and expanded to other hospitals within the EIT Health network, including other Spanish hospitals (Mutua de Terrassa and Hospital Germans Trias i Pujol), the Netherlands (Erasmus MC) and Belgium (University Hospital UZ Leuven, KU Leuven).

To find out more about the EIT Health project, please visit


    1. Garcia-Vidal, C., Moreno-García, E., Hernández-Meneses, M., Puerta-Alcalde, P., Chumbita, M., Garcia-Pouton, N., Linares, L., Rico, V., Cardozo, C., Martínez, J.A., García, F., Mensa, J., Castro, P., Nicolás, J.M., Muñoz, J., Vidal, D. and Soriano, A. (2020). Personalized therapy approach for hospitalized patients with COVID-19. Clinical Infectious Diseases.
    2. European Centre for Disease Prevention and Control. COVID-19 situation update worldwide, as of 3 August 2020. Available at: Last accessed: August 2020.
    3. Vincent, J.-L. and Taccone, F.S. (2020). Understanding pathways to death in patients with COVID-19. The Lancet Respiratory Medicine.

EIT Health-supported Vitadio earns permanent DiGA status

EIT Health-supported Vitadio earns permanent DiGA status

Learn how we helped them grow.

Find out more

Skill Sync: Bridging Europe's AI skills gap

Skill Sync: Bridging Europe's AI skills gap

Learn how we're addressing the AI skills gap.

Find out more

EIT Health-supported start-up Ochre Bio signs $1BN+ deal with Boehringer Ingelheim

EIT Health-supported start-up Ochre Bio signs $1BN+ deal with Boehringer Ingelheim

Learn how we supported their journey.

Find out more